240 related articles for article (PubMed ID: 23239087)
1. In vitro and in vivo pharmacological profile of the selective β3-adrenoceptor agonist mirabegron in rats.
Hatanaka T; Ukai M; Watanabe M; Someya A; Ohtake A; Suzuki M; Ueshima K; Sato S; Sasamata M
Naunyn Schmiedebergs Arch Pharmacol; 2013 Mar; 386(3):247-53. PubMed ID: 23239087
[TBL] [Abstract][Full Text] [Related]
2. Pharmacological profile of the selective β3-adrenoceptor agonist mirabegron in cynomolgus monkeys.
Hatanaka T; Ukai M; Watanabe M; Someya A; Ohtake A; Suzuki M; Ueshima K; Sato S; Masuda N
Naunyn Schmiedebergs Arch Pharmacol; 2013 Nov; 386(11):1001-8. PubMed ID: 23832377
[TBL] [Abstract][Full Text] [Related]
3. Efficacy of the combination of KPR-5714, a novel transient receptor potential melastatin 8 (TRPM8) antagonist, and β
Aizawa N; Fujimori Y; Nakanishi O; Hayashi T; Goi Y; Kobayashi JI; Fujita T
Eur J Pharmacol; 2021 May; 899():173995. PubMed ID: 33675781
[TBL] [Abstract][Full Text] [Related]
4. Long-term treatment with the beta-3 adrenoceptor agonist, mirabegron ameliorates detrusor overactivity and restores cyclic adenosine monophosphate (cAMP) levels in obese mice.
Calmasini FB; de Oliveira MG; Alexandre EC; da Silva FH; da Silva CPV; Candido TZ; Antunes E; Mónica FZ
Neurourol Urodyn; 2017 Aug; 36(6):1511-1518. PubMed ID: 27794199
[TBL] [Abstract][Full Text] [Related]
5. The novel β3-adrenoceptor agonist mirabegron reduces carbachol-induced contractile activity in detrusor tissue from patients with bladder outflow obstruction with or without detrusor overactivity.
Svalø J; Nordling J; Bouchelouche K; Andersson KE; Korstanje C; Bouchelouche P
Eur J Pharmacol; 2013 Jan; 699(1-3):101-5. PubMed ID: 23246623
[TBL] [Abstract][Full Text] [Related]
6. Protective effect of a β3-adrenoceptor agonist on bladder function in a rat model of chronic bladder ischemia.
Sawada N; Nomiya M; Hood B; Koslov D; Zarifpour M; Andersson KE
Eur Urol; 2013 Oct; 64(4):664-71. PubMed ID: 23838637
[TBL] [Abstract][Full Text] [Related]
7. Modulation of non-voiding activity by the muscarinergic antagonist tolterodine and the β(3)-adrenoceptor agonist mirabegron in conscious rats with partial outflow obstruction.
Gillespie JI; Palea S; Guilloteau V; Guerard M; Lluel P; Korstanje C
BJU Int; 2012 Jul; 110(2 Pt 2):E132-42. PubMed ID: 22734512
[TBL] [Abstract][Full Text] [Related]
8. Mirabegron (Myrbetriq) for overactive bladder.
Med Lett Drugs Ther; 2013 Feb; 55(1410):13-5. PubMed ID: 23459457
[No Abstract] [Full Text] [Related]
9. Effect of mirabegron, a novel β3-adrenoceptor agonist, on bladder function during storage phase in rats.
Hatanaka T; Ukai M; Watanabe M; Someya A; Ohtake A; Suzuki M; Ueshima K; Sato S; Kaku S
Naunyn Schmiedebergs Arch Pharmacol; 2013 Jan; 386(1):71-8. PubMed ID: 23224420
[TBL] [Abstract][Full Text] [Related]
10. Possible Involvement of Muscarinic Receptor Blockade in Mirabegron Therapy for Patients with Overactive Bladder.
Yamada S; Chimoto J; Shiho M; Okura T; Morikawa K; Wakuda H; Shinozuka K
J Pharmacol Exp Ther; 2021 May; 377(2):201-206. PubMed ID: 33658313
[TBL] [Abstract][Full Text] [Related]
11. Mirabegron relaxes urethral smooth muscle by a dual mechanism involving β3 -adrenoceptor activation and α1 -adrenoceptor blockade.
Alexandre EC; Kiguti LR; Calmasini FB; Silva FH; da Silva KP; Ferreira R; Ribeiro CA; Mónica FZ; Pupo AS; Antunes E
Br J Pharmacol; 2016 Feb; 173(3):415-28. PubMed ID: 26493129
[TBL] [Abstract][Full Text] [Related]
12. Mirabegron induces relaxant effects via cAMP signaling-dependent and -independent pathways in detrusor smooth muscle.
Maki T; Kajioka S; Itsumi M; Kareman E; Lee K; Shiota M; Eto M
Low Urin Tract Symptoms; 2019 Apr; 11(2):O209-O217. PubMed ID: 30632283
[TBL] [Abstract][Full Text] [Related]
13. Mirabegron causes relaxation of human and rat corpus cavernosum: could it be a potential therapy for erectile dysfunction?
Gur S; Peak T; Yafi FA; Kadowitz PJ; Sikka SC; Hellstrom WJ
BJU Int; 2016 Sep; 118(3):464-74. PubMed ID: 27124860
[TBL] [Abstract][Full Text] [Related]
14. A functional analysis of the influence of β3-adrenoceptors on the rat micturition cycle.
Sadananda P; Drake MJ; Paton JF; Pickering AE
J Pharmacol Exp Ther; 2013 Nov; 347(2):506-15. PubMed ID: 24008334
[TBL] [Abstract][Full Text] [Related]
15. Mirabegron, a β
Mendes-Silvério CB; Alexandre EM; Lescano CH; Antunes E; Mónica FZ
Eur J Pharmacol; 2018 Jun; 829():79-84. PubMed ID: 29654782
[TBL] [Abstract][Full Text] [Related]
16. Involvement of β3-adrenoceptors in the inhibitory control of cholinergic activity in human bladder: Direct evidence by [(3)H]-acetylcholine release experiments in the isolated detrusor.
D' Agostino G; Maria Condino A; Calvi P
Eur J Pharmacol; 2015 Jul; 758():115-22. PubMed ID: 25861936
[TBL] [Abstract][Full Text] [Related]
17. GW427353 (solabegron), a novel, selective beta3-adrenergic receptor agonist, evokes bladder relaxation and increases micturition reflex threshold in the dog.
Hicks A; McCafferty GP; Riedel E; Aiyar N; Pullen M; Evans C; Luce TD; Coatney RW; Rivera GC; Westfall TD; Hieble JP
J Pharmacol Exp Ther; 2007 Oct; 323(1):202-9. PubMed ID: 17626794
[TBL] [Abstract][Full Text] [Related]
18. Combined treatment with a β
Imamura T; Ogawa T; Minagawa T; Nagai T; Suzuki T; Saito T; Yokoyama H; Nakazawa M; Ishizuka O
Neurourol Urodyn; 2017 Apr; 36(4):1026-1033. PubMed ID: 27367573
[TBL] [Abstract][Full Text] [Related]
19. The metabolic effects of mirabegron are mediated primarily by β
Dehvari N; Sato M; Bokhari MH; Kalinovich A; Ham S; Gao J; Nguyen HTM; Whiting L; Mukaida S; Merlin J; Chia LY; Wootten D; Summers RJ; Evans BA; Bengtsson T; Hutchinson DS
Pharmacol Res Perspect; 2020 Oct; 8(5):e00643. PubMed ID: 32813332
[TBL] [Abstract][Full Text] [Related]
20. Mirabegron.
Goulooze SC; Cohen AF; Rissmann R
Br J Clin Pharmacol; 2015 Oct; 80(4):762-4. PubMed ID: 25819590
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
